NDA 020675 · Abbvie
Urso 250
Ursodiol · Oral · Bile Acid
OrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Jan 12, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Dec 10, 1997
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
202
58 Phase 3, 24 recruiting
FAERS reports
22,309
17,866 serious, 3,055 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 12, 2023.
URSO 250 and URSO Forte (ursodiol) tablets are indicated for the treatment of patients with primary biliary cholangitis (PBC). URSO 250 and URSO Forte (ursodiol) tablets are bile acids indicated for the treatment of patients with primary biliary cholangitis. ( 1 )
Mechanism: Ursodiol, a naturally occurring hydrophilic bile acid, derived from cholesterol, is present as a minor fraction of the total human bile acid pool. Oral administration of ursodiol increases this fraction in a dose related manner, to become the major biliary acid, replacing/displacing toxic concentrations of endogenous hydrophobic bile acids that tend to accumulate in cholestatic liver disease. In addition to the replacement and displacement of toxic bile acids, other mechanisms of action include cytoprotection of the injured bile duct epithelial cells (cholangiocytes) against toxic effects of...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Ursodiol" as an intervention, any sponsor and status, largest first.
- Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by StatinPivotal-lookingStatus unknown
First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
NCT05500937 · 1,000 participants (planned) · Start Mar 1, 2021 · Primary completion Dec 31, 2023
Drug: UDCA · For: Diabetes Mellitus
Sites: Xi’an, China
- MITE in the Treatment of Dyspepsia After CholecystectomyPivotal-lookingStatus unknown
Xinhua Hospital, Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
NCT04786795 · 990 participants (planned) · Start Mar 1, 2021 · Primary completion Feb 1, 2022
Drug: Compound Azintamide Enteric-coated Tablets; Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets · For: Patients With Dyspeptic Symptoms After Cholecystectomy
- Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis CPivotal-lookingCompleted
Tanabe Pharma CorporationIndustry
NCT00200343 · 596 participants · Start Jul 2002
Drug: Ursodeoxycholic acid 150mg / day; Ursodeoxycholic acid 600mg / day and 1 more · For: Chronic Hepatitis C
Sites: Hongo, Bunkyo-ku, Tokyo, Japan
- Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With MetforminPivotal-lookingCompleted
Shenzhen HighTide Biopharmaceutical Ltd.Industry
NCT06353347 · 551 participants · Start Nov 13, 2023 · Primary completion Dec 12, 2024
Drug: HTD1801; Placebo · For: Type 2 Diabetes Mellitus
Sites: Baotou, China; Beijing, China; Changchun, China · 64 sites in all
- Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac SurgeryPivotal-lookingCompleted
China National Center for Cardiovascular DiseasesGovernment (non-federal)
NCT05690646 · 491 participants · Start Jan 28, 2023 · Primary completion Mar 24, 2023
Drug: Nirmatrelvir/ritonavir; Ursodeoxycholic acid · For: Cardiac Surgery
Sites: Beijing, China
- A Study to Evaluate the Efficacy and Safety of CnU Capsule 750 mg in Patients With Cholesterol Gallstones(GB Stones).Pivotal-lookingRecruiting
Myungmoon Pharma. Co. Ltd.Industry
NCT07005752 · 484 participants (planned) · Start Jul 28, 2025 · Primary completion Nov 10, 2027
Drug: CnU cap. 250mg & Ursa placebo tab. 200mg; Ursa tab. 200mg & CnU placebo cap. 250mg · For: Cholesterol Cholelithiasis
Sites: Ansan, South Korea; Bucheon-si, South Korea; Suwon, South Korea · 13 sites in all
- To Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After GasterectomyPivotal-lookingCompleted
Daewoong Pharmaceutical Co. LTD.Industry
NCT05410535 · 431 participants · Start Sep 15, 2021 · Primary completion Oct 28, 2022
Drug: Patients who continued UDCA 300mg medication · For: Gastric Cancer
Sites: Seoul, South Korea
- Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 DiabetesPivotal-lookingCompleted
Shenzhen HighTide Biopharmaceutical Ltd.Industry
NCT06350890 · 408 participants · Start Nov 5, 2023 · Primary completion Dec 12, 2024
Drug: HTD1801; Placebo · For: T2DM (Type 2 Diabetes Mellitus)
Sites: Xuancheng, China; Beijing, China; Chongqing, China · 56 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,842
- pruritus1,326
- diarrhoea1,284
- fatigue1,129
- nausea1,091
- pyrexia1,016
- drug ineffective987
- pneumonia791
- death730
- vomiting714
- headache647
- dyspnoea609
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Urso Forte (Ursodiol)
2024 spending
$29K
Beneficiaries
19
25 claims
Per beneficiary
$1,535
$9.28 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $558,871 |
| 2021 | $526,474 |
| 2022 | $499,669 |
| 2023 | $391,797 |
| 2024 | $29,161 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.
Nevens F, Andreone P, Mazzella G, et al. · N Engl J Med 2016 · Clinical Trial, Phase III, Multicenter Study
- Role of ursodeoxycholic acid in neonatal indirect hyperbilirubinemia: a systematic review and meta-analysis of randomized controlled trials.
Lazarus G, Francie J, Roeslani RD, et al. · Ital J Pediatr 2022 · Meta-Analysis, Systematic Review
- Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol.
Mason AL, Lindor KD, Bacon BR, et al. · Aliment Pharmacol Ther 2008 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis.
Hansen JD, Kumar S, Lo WK, et al. · Dig Dis Sci 2013 · Meta-Analysis, Systematic Review
- Results of long-term ursodiol treatment for patients with primary biliary cirrhosis.
Jorgensen R, Angulo P, Dickson ER, et al. · Am J Gastroenterol 2002 · Clinical Trial, Randomized Controlled Trial
- A pilot study of etanercept in the treatment of primary sclerosing cholangitis.
Epstein MP, Kaplan MM · Dig Dis Sci 2004 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: AbbVie · Also marketed as Urso Forte
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.